In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 94, Issue 1, 2010, Pages 1-10

  Chimote, G ^a   Banerjee, R ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

DPPC; Isoniazid; Pulmonary surfactant; Pulmonary tuberculosis

Indexed keywords

ALVEOLAR DEPOSITION; ANTIMYCOBACTERIAL ACTIVITY; DIPALMITOYL PHOSPHATIDYLCHOLINE; DPPC LIPOSOME; DRUG ENTRAPMENT; ENTRAPMENT EFFICIENCY; IN-VITRO; IN-VITRO EVALUATION; INHALABLE DRUG; LUNG SURFACTANTS; PULMONARY DRUG DELIVERY; PULMONARY SURFACTANTS; PULMONARY TUBERCULOSIS; SURFACTANT ACTION; SUSTAINED RELEASE;

ADSORPTION; BIOCOMPATIBILITY; CONTROLLED DRUG DELIVERY; HYDRAZINE; LIPOSOMES; SURFACE ACTIVE AGENTS; SURFACE TENSION;

PHOSPHOLIPIDS;

DIPALMITOYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; ISONIAZID; LIPOSOME; SURFACTANT;

ADSORPTION; ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FIBROBLAST; HUMAN; HUMAN CELL; LUNG ALVEOLUS; LUNG TUBERCULOSIS; MOUSE; NEBULIZATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; SURFACE TENSION; SUSTAINED DRUG RELEASE;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADSORPTION; ANIMALS; ANTITUBERCULAR AGENTS; BIOCOMPATIBLE MATERIALS; CELL LINE; COMPLEMENT ACTIVATION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; ISONIAZID; LIPOSOMES; MATERIALS TESTING; MICE; MICROBIAL SENSITIVITY TESTS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PULMONARY SURFACTANTS; SURFACE PROPERTIES; TUBERCULOSIS, PULMONARY;

EID: 77954109601     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31608     Document Type: Article

References (42)

1. World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing. WHO Report 2007, Document WHO/HTM/TB/2007.376 Geneva, Switzerland: World Health Organization, 2007.
2. Selassie A, Pozsik C, Wilson D, Ferguson P. Why pulmonary tuberculosis recurs: A population based epidemiological study. Ann epidemiol 2005;15:519-525. (Pubitemid 40982127)
3. Chimote G, Banerjee R. Lung surfactant dysfunction in tuberculosis: Effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity. Colloids Surf B 2005;45: 215-223.
4. Class RN, Pacheco MR. Spontaneous tension pneumomediastinum complicating pulmonary tuberculosis. Chest 1965;48:621-627.
5. Wang Z, Schwab U, Rhoades E, Chess P, Russell D, Notter R. Peripheral cell wall lipids of Mycobacterium tuberculosis are inhibitory to surfactant function. Tuberculosis 2008;88:175-186.
6. Goerke J, Clements JA. Handbook of Physiology, Vol. III. Bethesda, MD: American Physiology Society Press; 1986.
7. Enhorning G. Pulmonary surfactant function studied with the pulsating bubble surfactometer (PBS) and the capillary surfactometer (CS). Biochem Physiol A Mol Integr Physiol 2001;129:221-226.
8. Duffett M, Choong K, Ng V, Randolph A, Cook DJ. Surfactant therapy for acute respiratory failure in children: A systematic review and meta-analysis. Critical Care 2007;11:R66.
9. Saigal S, Robertson C, Sankaran K, Bingham W, Casiro O, MacMurray B, Whitfield M, Long W. One year outcome in 232 premature infants with birth weights of 750 to 1249 grams and respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air placebo. J Pediatr 1995;126:S61-S67.
10. Banerjee R, Bellare JB. Scoring of surface parameters of physiological relevance to surfactant therapy in respiratory distress syndrome. J Appl Physiol 2001;90:1447-1454. (Pubitemid 32220931)
11. Goerke J. Pulmonary surfactant: Functions and molecular composition. Biochim Biophys Acta 1998;1408:79-89.
12. Haagsman HP, Diemel RV. Surfactant-associated proteins: functions and structural variation. Biochem Physiol A Mol Integr Physiol 2001;129:91-108.
13. Chimote G, Banerjee R. Effect of antitubercular drugs on dipalmitoylphosphatidylcholine monolayers: Implications for drug-loaded surfactants. Respir Physiol Neurobiol 2005;145:65-77. (Pubitemid 40137997)
14. Nagarsenker MS, Londhe VY. Preparation and evaluation of a liposomal formulation of sodium cromoglicate. Int J Pharm 2003; 251:49-56. (Pubitemid 36071459)
15. King RJ, Clements JA. Surface active materials from dog lung. II. Composition and physiological correlations. Am J Physiol 1972; 223:715-726.
16. European Pharmacopeian Secretariat. European Pharmacopoeia, 4th ed. European Pharmacopeian Secretariat: Strasbourg; 2004.
17. Hallworth GW, Westmoreland DG. The twin impinger: A simple device for assessing the delivery of drug from metered pressurized aerosol inhaler. J Pharm Pharmacol 1987;39:966-972.
18. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the Sulforhodamine B colorimetric assay. J Immunol Methods 1997;208:151-158.
19. ASTM active standards: F813-01. Standard practice for direct contact cell culture evaluation of materials for medical devices.
20. Sharma P, Sharma JD. In vitro hemolysis of human erythrocytes - By plant extracts with antiplasmodial activity. J Ethnopharmacol 2001;74:239-243.
21. Hugli TE, Muller-Eberhard HJ. Anaphylatoxins:C3a and C5a. Adv Immunol 1978;26:1-53.
22. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampicin encapsulated in lung specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 1997;41:1211-1214. (Pubitemid 27231415)
23. Enhorning G, Duffy LC, Welliver RC. Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995;151:554-556.
24. Rachana, Banerjee R. Interactions between haematological derivatives and dipalmitoylphosphatidylcholine: Implications for adult respiratory distress syndrome. Colloids Surf B 2004;34:95-104.
25. Veen AV, Mouton JW, Gommers D, Lachmann B. Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br J Pharmacol 1996;119: 1145-1148. (Pubitemid 26385984)
26. Kharash VS, Sweeney TD, Fredberg J, Lehr J, Damokosh AI, Avery MA, Brain JD. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 1991;144:909-913.
27. Sorokoumova GM, Selishcheva AA, Malikova NM, Minina AS, Shvets VI. Incorporation of isoniazid into liposomes with different lipid composition. Bull Exp biol Med 2004;137:17-19. (Pubitemid 39137245)
28. Wasserman M, Beltrán RM, Quintana FO, Mendoza PM, Orozco LC, Rodriguez G. A simple technique for entrapping rifampicin and isoniazid into liposomes. Tubercle 1986;67:83-90. (Pubitemid 16080225)
29. Leonenko Z, Fincot E, Vassiliev V, Amrein M. Effect of cholesterol on the physical properties of pulmonary surfactant films: Atomic force measurements study. Ultramicroscopy 2006;106: 687-694. (Pubitemid 43994313)
30. Orozco LC, Quintana FO, Beltrán RM, Moreno I, Wasserman M, Rodriguez G. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Tubercle 1986; 67:91-97.
31. Veen A, Mouton JW, Gommers D, Kluytmans JA, Dekkers P, Lachmann B. Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime and tobramycin. Antimicrob Agents Chemother 1995;39:329-333.
32. Golyshevskaia VI, Selishcheva AA, Martynova LP, Lepekha LN, Kalashnikova TM, Kornilova ZK, Erokhin VV, Rozenberg OA. Evaluation of the efficiency of activity of the liposomal form of isoniazid against different types of mycobacteria in vitro. Problemy tuberkuleza 2006;8:61-64.
33. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-986.
34. Suarez S, Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Respirable PLGA microspheres containing Rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm Res 2001;18:1315-1319.
35. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001; 18:1405-1410.
36. Hall SB, Lu RZ, Venkitaraman AR, Hyde RW, Notter RH. Inhibition of pulmonary surfactant by oleic acid: Mechanisms and characteristics, J Appl Physiol 1992;72:1708-1716.
37. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26:298-303. (Pubitemid 41338657)
38. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005;85:227-234. (Pubitemid 40805619)
39. Hall SB, Lu RZ, Venkitaraman AR, Hyde RW, Notter RH. Inhibition of pulmonary surfactant by oleic acid: Mechanisms and characteristics. J Appl Physiol 1992;72:1708-1716.
40. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG, Hall WJ. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983;308:1443-1447.
41. Schaad UB, Krucko WJ, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987;111:599-605. (Pubitemid 17140544)
42. Brain JD, Valberg PA. Deposition of aerosols in the respiratory tract. Am Rev Resp Dis 1979;120:1325-1373.